This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
Lentiviral vector-based immunotherapies
Theravectys, spun off from Institut Pasteur in 2005 by Dr. Pierre Charneau, develops lentiviral vector vaccines and immunotherapies for CMV, TB, and cancer under exclusive licenses.
No data available
No FAQ items available.